What is Range Biotechnologies?
Founded in 2022 and headquartered in San Francisco, California, Range Biotechnologies is a biotechnology company specializing in proteomics. The company aims to leverage advancements in protein science to develop innovative solutions within the healthcare sector. Its focus on proteomics positions it at the forefront of understanding biological processes at a molecular level, which is critical for drug discovery, diagnostics, and personalized medicine. The recent major strategic investment signals strong confidence from the investment community in Range Biotechnologies' technological approach and market potential.
How much funding has Range Biotechnologies raised?
Range Biotechnologies has raised a total of $5.2M across 1 funding round:
Angel/Seed
$5.2M
Angel/Seed (2023): $5.2M with participation from Civilization Ventures, Pear, Page One Ventures, and ARTIS Ventures
Key Investors in Range Biotechnologies
Civilization Ventures
Civilization Ventures is a venture capital firm specializing in health tech and biopharma, with a focus on preventative, personalized, and regenerative healthcare. They invest in innovative companies and support founders through their extensive network and capital.
Pear
Pear VC is an early-stage investment firm that partners with founders at the pre-seed and seed stages, offering support in talent recruitment, fundraising, and go-to-market strategies to foster startup growth.
ARTIS Ventures
ARTIS Ventures is a venture capital fund dedicated to Tech Bio+Health, investing in data-driven life sciences companies that leverage AI and engineering for personalized therapeutics and efficient drug discovery.
What's next for Range Biotechnologies?
With the recent influx of capital, Range Biotechnologies is poised for significant growth and expansion. The enterprise-level funding suggests a strategic phase focused on scaling operations, advancing research and development pipelines, and potentially forging key partnerships. The company's trajectory indicates a move towards solidifying its position in the competitive biotechnology market, with a likely emphasis on translating its proteomics expertise into tangible therapeutic or diagnostic products. Future developments will likely center on clinical validation, regulatory approvals, and broader market adoption.
See full Range Biotechnologies company page
